"Lake Health/University Hospitals Seidman Cancer is Northeast Ohio's only comprehensive community cancer center, providing specialized care to patients in Lake, Geauga and Ashtabula Counties. We are accredited by the American College of Radiology, the Quality Oncology Practice Initiative Certification Program, the National Accreditation Program for Breast Centers, and the Commission on Cancer of the American College of Surgeons."

During the past decade, UH Seidman Cancer Center at Lake Health Mentor Campus conducted 89 clinical trials. In the 10-year time frame, 89 clinical trials started and 111 clinical trials were completed, i.e. on average, 124.7% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 63 clinical trials were completed. i.e. 225% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UH Seidman Cancer Center at Lake Health Mentor Campus" #1 sponsor was "National Cancer Institute (NCI)" with 80 trials, followed by "Gynecologic Oncology Group" with 45 trials sponsored, "SWOG Cancer Research Network" with 21 trials sponsored, "NRG Oncology" with 17 trials sponsored and "Radiation Therapy Oncology Group" with 17 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UH Seidman Cancer Center at Lake Health Mentor Campus" #1 collaborator was "National Cancer Institute (NCI)" with 129 trials as a collaborator, "NRG Oncology" with 59 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "Radiation Therapy Oncology Group" with 4 trials as a collaborator and "Gynecologic Oncology Group" with 3 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "UH Seidman Cancer Center at Lake Health Mentor Campus" are "Recurrent Ovarian Carcinoma" (24 trials), "Recurrent Fallopian Tube Carcinoma" (18 trials), "Recurrent Primary Peritoneal Carcinoma" (17 trials), "Cervical Adenocarcinoma" (15 trials) and "Cervical Adenosquamous Carcinoma" (14 trials). Many other conditions were trialed in "UH Seidman Cancer Center at Lake Health Mentor Campus" in a lesser frequency.

Most popular intervention types in "UH Seidman Cancer Center at Lake Health Mentor Campus" are "Drug" (164 trials), "Other" (131 trials), "Biological" (80 trials), "Radiation" (58 trials) and "Procedure" (42 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (81 trials), "Quality-of-Life Assessment" (49 trials), "Paclitaxel" (38 trials), "Carboplatin" (30 trials) and "Questionnaire Administration" (28 trials). Other intervention names were less common.

The vast majority of trials in "UH Seidman Cancer Center at Lake Health Mentor Campus" are 105 trials for "Female" genders, 93 trials for "All" genders and 14 trials for "Male" genders.

Currently, there are NaN active trials in "UH Seidman Cancer Center at Lake Health Mentor Campus". undefined are not yet recruiting, 31 are recruiting, 78 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 84 completed trials in UH Seidman Cancer Center at Lake Health Mentor Campus, 3 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in UH Seidman Cancer Center at Lake Health Mentor Campus, 6 "Phase 1" clinical trials were conducted, 113 "Phase 2" clinical trials and 95 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".